Cargando…

Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia

Novel agents have made the management of chronic lymphocytic leukemia (CLL) more promising and personalized. However, long-term treatment is still warranted which may result in toxicity and resistance. Thus, new combination therapy may help achieve deeper remission and limited-duration therapy. Hist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kong, Yi-Lin, Pan, Bi-Hui, Liang, Jin-Hua, Zhu, Hua-Yuan, Wang, Li, Xia, Yi, Wu, Jia-Zhu, Fan, Lei, Li, Jian-Yong, Xu, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485718/ https://www.ncbi.nlm.nih.gov/pubmed/32855355 http://dx.doi.org/10.18632/aging.103536

Ejemplares similares

Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease
por: He, Jingsong, et al.
Publicado: (2018)

Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer
por: Zhang, Na, et al.
Publicado: (2020)

Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia
por: El-Khoury, V, et al.
Publicado: (2014)

Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy
por: He, Yanjuan, et al.
Publicado: (2021)

Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner
por: Yuan, Xiang-Gui, et al.
Publicado: (2019)

Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine
por: Yao, Yushi, et al.
Publicado: (2013)

Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy
por: Stankov, Metodi V., et al.
Publicado: (2013)

The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF-κB pathway in multiple myeloma cells
por: Liu, Zhaoyun, et al.
Publicado: (2019)

PB1856: DEMETHYLATING AGENTS AND HISTONE DEACETYLASE INHIBITORS AS NEW THERAPEUTIC STRATEGIES IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Jorge #, J., et al.
Publicado: (2022)

Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC
por: Zhang, Ningning, et al.
Publicado: (2019)

Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells
por: Zhao, Haijun, et al.
Publicado: (2022)

Successful treatment of early onset Epstein-Barr virus-negative T-cell lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation with histone deacetylase inhibitor chidamide
por: Fu, Hua-Rui, et al.
Publicado: (2021)

Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
por: Huang, Ying, et al.
Publicado: (2011)

Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies
por: Sandonà, Martina, et al.
Publicado: (2023)

Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53
por: Mrakovcic, Maria, et al.
Publicado: (2017)

Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer
por: Zhang, Qingyuan, et al.
Publicado: (2018)

A Novel Mechanism of Action of Histone Deacetylase Inhibitor Chidamide: Enhancing the Chemotaxis Function of Circulating PD-1(+) Cells From Patients With PTCL
por: Wei, Chong, et al.
Publicado: (2021)

Chidamide enhances cytotoxicity of doxorubicin by promoting autophagy and apoptosis in breast cancer
por: Li, Jieqing
Publicado: (2023)

Histone deacetylase functions and therapeutic implications for adult skeletal muscle metabolism
por: Molinari, Susanna, et al.
Publicado: (2023)

Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib
por: Xu, Li, et al.
Publicado: (2020)

Histone Deacetylase 3: A Potential Therapeutic Target for Atherosclerosis
por: Jiang, Li-Ping, et al.
Publicado: (2022)

Targeting Histone Deacetylases for Cancer Therapy: From Molecular Mechanisms to Clinical Implications
por: Li, Zhiming, et al.
Publicado: (2014)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Roles of Histone Deacetylases in Acute Myeloid Leukemia With Fusion Proteins
por: Zhang, Juan, et al.
Publicado: (2021)

Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma
por: Wen, Tingyu, et al.
Publicado: (2022)

Corrigendum: Histone deacetylase functions and therapeutic implications for adult skeletal muscle metabolism
por: Molinari, Susanna, et al.
Publicado: (2023)

Therapeutic effects of histone deacetylase inhibitors in a murine asthma model
por: Ren, Yuan, et al.
Publicado: (2016)

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

The Role of Histone Acetyltransferases and Histone Deacetylases in Photoreceptor Differentiation and Degeneration
por: Zhao, Meng, et al.
Publicado: (2020)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Latent HIV in primary T lymphocytes is unresponsive to histone deacetylase inhibitors
por: Sahu, Gautam K, et al.
Publicado: (2011)

A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer
por: Hu, Xingsheng, et al.
Publicado: (2016)

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
por: Li, Guo, et al.
Publicado: (2020)

Therapeutic Interaction of Apatinib and Chidamide in T-cell Acute Lymphoblastic Leukemia through Interference with Mitochondria Associated Biogenesis and Intrinsic Apoptosis
por: Zhong, Mengya, et al.
Publicado: (2021)

Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer
por: Bi, Jianling, et al.
Publicado: (2022)

Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia
por: Chen, Kai, et al.
Publicado: (2020)

Histone deacetylase inhibitors: clinical implications for hematological malignancies
por: Tambaro, Francesco Paolo, et al.
Publicado: (2010)

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors
por: Han, Yu, et al.
Publicado: (2022)

Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism
por: Li, Gangping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8q2pd8kte2tf7v6d2r7tdancgs